Drug Profile

Recombinant adjuvanted respiratory syncytial virus vaccine - MAXVAX Biotechnology

Latest Information Update: 10 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MAXVAX Biotechnology
Class Protein vaccines; Respiratory syncytial virus vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Respiratory syncytial virus infections

Most Recent Events

01 Jun 2026 MAXVAX Biotechnology plans a study for Respiratory Syncytial Virus (RSV) (IM), in June 2026 (NCT07618325)
22 Oct 2025 Phase-III clinical trials in Respiratory syncytial virus infections (Prevention, In the elderly) in China (IM) (NCT07272434)
13 Nov 2024 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention) in China (IM) (NCT06642558)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com